Clinical trials: Cancer of the Esophagus
Esophageal Neoplasm, Esophageal Disease
Outcomes After Esophageal Cancer Surgery
Background Esophageal carcinoma is the sixth leading cause of cancer -related mortality and the eighth most common cancer worldwide The incidence is increasing rapidly The overall 5-year survival ranges from 15% to 25% in the…
- Trial name
- FREGAT I (NCT01927016)
- Testing
- Esophagectomy
- Where
- France
- Volunteers
- 2,944 people
- Sponsor
- University Hospital, Lille
Esophagus Adenocarcinoma
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with…
- Trial name
- NCT05713838
- Testing
- Durvalumab, FLOT, mFOLFOX-6
- Where
- 22 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
Esophageal Squamous Cell Carcinoma
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if immune microenvironment modification could improve the effect of chemoradiotherapy for patients with local advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06401447
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Immunotherapy;Envafolimab; Esophageal Cancer
Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer
Big breakthroughs have been made in the combination therapy of immune checkpoint inhibitors when it comes to the neoadjuvant therapy of esophageal cancer.
- Trial name
- NCT05828381
- Testing
- Envafolimab, Abraxane, Cisplatin
- Volunteers
- 33 people
- Sponsor
- Fujian Medical University Union Hospital
Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer
Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy
This study assesses for early signs of damage to the heart following chest radiation therapy using both imaging (cardiac magnetic resonance imaging and cardiac positron emission tomography) and changes in blood biomarkers.
- Conditions
- Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer
- Trial name
- NCT05717998
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma
AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the safety and efficacy of AK104 plus concurrent chemoradiation therapy in unresectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05594914
- Testing
- AK104
- Volunteers
- 47 people
- Sponsor
- The First Affiliated Hospital of University of South China
Esophageal Squamous Cell Carcinoma
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer…
- Trial name
- NCT04644250
- Testing
- Toripalimab, Paclitaxel liposome/Carboplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Wei Ren
Esophageal Dysplasia
Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital
Esophageal squamous cell cancer (ESCC) is common in the developing world, and is the leading cancer diagnosis at Tenwek Hospital in southwestern Kenya.
- Trial name
- STEP (NCT01981876)
- Where
- Kenya
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Tenwek Hospital
Esophageal Cancer
Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy
The purpose of this study is to determine the safety and efficacy of the side-to-side stapled intrathoracic esophagogastric anastomosis in Ivor-Lewis Oesophagectomy.
- Trial name
- NCT01242124
- Testing
- side-to-side stapled esophagogastric anastomosis, circular-stapled esophagogastric anastomosis
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Gastric Cancer
Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.
- Trial name
- MAGECmultiDiCE (NCT06346080)
- Testing
- Survey
- Where
- Belgium
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Lung Cancer, Esophageal Cancer
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
This study aims to investigate the impact of immunotherapy on the immune status of tumor microenvironment and peripheral blood of chest cancer patients.
- Trial name
- NCT06790797
- Testing
- In vitro stimulation of Pbmc with tumor antigen nanoparticles
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhao Jun
Esophageal Squamous Cell Carcinoma, Esophageal Cancer
Esophageal cAncer Screening Trial
This multicenter study aims to include 15000 participants undergoing screening upper gastrointestinal endoscopy and establish a risk prediction model for esophageal squamous cell carcinoma and esophagogastric junctional (EGJ)…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- EAST (NCT04609813)
- Testing
- Sponge cytological test
- Where
- China
- Volunteers
- 14,597 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Esophageal Neoplasms
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
This randomized controlled trial will evaluate the effects of preoperative enteral immunonutrition in esophageal cancer patients undergoing neoadjuvant therapy.
- Trial name
- POINT (NCT04513418)
- Testing
- Preoperative immunonutrition
- Where
- 6 sites in China
- Volunteers
- 244 people
- Sponsor
- Hecheng Li M.D., Ph.D
Esophageal Squamous Cell Carcinoma
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of sintilimab combined with concurrent chemotherapy as a neoadjuvant treatment for patients with operable esophageal squamous cell carcinoma.
- Trial name
- NCT05174325
- Testing
- Sintilimab + chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Sintilimab and Anlotinib in Combination With Chemotherapy
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
The study focused on patients with T2-4NxM0 resectable esophageal carcinoma. Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200…
- Trial name
- NCT06015035
- Testing
- Sintilimab and anlotinib in combination with chemotherapy
- Where
- 2 sites in China
- Volunteers
- 17 people
- Sponsor
- Tang-Du Hospital
Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma participants who have failed upfront standard of care chemotherapy.
- Trial name
- RiME (NCT03995017)
- Testing
- Rucaparib, Ramucirumab, Nivolumab
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Kansas Medical Center
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.